Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Alexion Pharmaceuticals Q4 Profit Rises - Quick Facts

RELATED NEWS
Trade ALXN now with 

Alexion Pharmaceuticals Inc. (ALXN: Quote) reported fourth-quarter GAAP net income of $81.0 million, or $0.40 per share up from $48.2 million, or $0.25 per share in the year ago quarter.

Non-GAAP net income for the quarter was $122.3 million, or $0.60 per share, compared to non-GAAP net income of $80.5 million, or $0.41 per share last year. Analysts polled by Thomson Reuters expected the company to report earnings of $0.53 per share for the quarter. Analysts' estimates typically exclude special items.

Net product sales of Soliris (eculizumab) was $320.5 million, compared to $227.6 million for the same period in 2011. Twenty analysts had consensus revenue estimate of $316.49 million for the quarter.

The year-on-year increase in net product sales of 41 percent reflected steady additions of new patients with paroxysmal nocturnal hemoglobinuria (PNH) globally, and an increasing number of new patients with atypical Hemolytic Uremic Syndrome (aHUS) commencing Soliris treatment.

In 2013, worldwide net product sales are expected to be within a range of $1.490 billion to $1.505 billion. On a non-GAAP basis, R&D expenses are expected to be in the range of $285 to $295 million, and SG&A expenses in the range of $425 to $435 million.. Based on a forecast of approximately 205 million diluted shares outstanding, Alexion is providing guidance of $2.82 to $2.92 for non-GAAP earnings per share for the year.

Analysts expect the company to report earnings of $2.81 per share on revenues of $1.49 billion for fiscal 2013.

Register
To receive FREE breaking news email alerts for Alexion Pharmaceuticals Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
With a substantial decrease in energy prices more than offsetting higher prices for food and shelter, the Labor Department released a report on Wednesday showing an unexpected drop in U.S. consumer prices in the month of August. After ending the previous session notably higher, stocks may show a lack of direction in early trading on Wednesday. The major index futures are currently pointing to a roughly flat open for the markets, with the Dow futures down by just 2 points. Policymakers of the Bank of England split on the rate decision in September as two members repeated their call for a quarter- point hike given the rapid absorption of slack with economic growth. The British unemployment rate continued to fall in July, reaching the lowest since late 2008, and jobless claims declined more than expected in August.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.